Significantly greater relative weight loss
Our studies show that there is a significant difference in relative weight loss after one year of treatment with Evira compared to traditional treatment. The treatment with Evira is also less resource-intensive than the treatments that form the basis of the results presented under USPSTF in the figure.
​
The figure below shows the reduction of overweight in WHO BMI SDS during a first year of treatment in randomly selected patients. BMI SDS is a relative measure of obesity used for children.
Comparison between treatment results in WHO BMI SDS after one year of treatment with Evira and traditional treatment according to the Child Obesity Register in Sweden (BORIS) as well as results presented in a meta-study for children who received at least 26 hours of professional support over a year compiled by
Significantly better
than traditional treatment
Evira has been validated in clinical studies and used in clinical practice for several years with very good results.
Happier families
In one of our studies, 78% of families were satisfied with the treatment results after one year of treatment with Evira compared to only 11% among parents in traditional treatment.
Fewer canceled visits
Among patients treated with Evira, the number of canceled visits decreased by 45% during a
six-month period, where only
40% of patients canceled at least one visit, compared to 85% with traditional treatment.
Lower cost
Evira has unmatched results in clinical studies for children where no drugs or surgery were used. Those who received treatment with Evira had, on average, twice as good a treatment effect compared to corresponding groups who received traditional treatment.
Research about Evira
Evira has been evaluated clinically and in a research context in various forms for several years. Treatment with Evira gives, on average, twice as good an effect compared to traditional treatment.
​
One-year study in clinical practice
In our latest one-year study together with prominent researchers from Karolinska Institutet, the first 107 patients at the Martina Children's Hospital Center for Weight Health were able to use Evira's platform and treatment method for a year. A matched control group of 321 patients was randomly selected from the national quality registry BORIS who received traditional childhood obesity treatment during the same time period. The intervention group using Evira had a relative weight loss of 0.30 WHO BMI SDS units, compared to the control group which averaged 0.15 WHO BMI SDS units.
Mean change in WHO BMI SDS for Evira patients (dark gray) and the control group of BORIS patients (light gray) after 1 year of treatment divided by sex, age and degree of obesity in the 1-year study.
​
In addition to being able to see twice as good treatment results with Evira compared to traditional treatment, we were able to see a big effect on teenagers - a treatment group that has been very difficult to reach before with traditional treatment.
​
Feasibility study
In Evira's early days, the platform was tested in a small feasibility study at three clinics over a period of six months. The study showed a good treatment effect after six months compared to traditional treatment and showed that patients and therapists were very satisfied with the platform.
.png)
Change in WHO BMI SDS from baseline to follow-up at three and six months for intervention and control groups in the feasibility study.
​
Almost everyone in the intervention group who used Evira reported that Evira helped them reach their treatment goals, and that it was easier to get in touch with therapists at the clinic. The families who used Evira were significantly more satisfied with the treatment results compared to the control group.
​
Doctoral thesis by Linnea Johansson
Linnea Johansson, Ph. D, has researched mobile health interventions with Evira as the main focus in his doctoral thesis . She brings up several important lessons about how to think about digital treatment and analyzes what worked and what didn't work during Evira's development period. She concludes by stating that digital health interventions together with clinical visits, such as Evira, provide a better treatment effect than behavioral treatment alone. Linnea also places great emphasis on the importance of technical maturity of digital systems, as well as the importance of teaching clinical staff how treatment with the help of digital support systems should be carried out.
EurEvira - international multicenter study
(ongoing)
EurEvira is an international multicenter study that is ongoing in several European countries to evaluate how Evira together with local childhood obesity treatment works in countries other than Sweden.
​
The study is currently being conducted at the following sites in Europe.
Published research
”Effect of an interactive mobile health support system and daily weight measurements for pediatric obesity treatment, a one-year pragmatical clinical trial”, Emilia Hagman, Linnea Johansson, Claude Kollin, Erik Marcus, Andreas Drangel, Love Marcus, Claude Marcus, Pernilla Danielsson, International Journal of Obesity, online 31 maj 2022, doi: 10.1038/s41366-022-01146-8.
Thesis for doctoral degree(Ph.D) 2022. Mobile Health interventiopns and cardiorespiratory fitness in pediatric obesity.​Linnea Johansson, Karolinska Institutet.
A novel interactive mobile health support system for pediatric obesity treatment: a randomized controlled feasibility trial. ​Linnea Johansson, Emilia Hagman, Pernilla Danielsson. BMC Pediatr. 2020;20:447.
​
